|
Acadia Pharmaceuticals, Inc. - Company Profile Snapshot
| Company Profile: |
Acadia Pharmaceuticals, Inc. |
| Ticker: |
ACAD |
| Exchanges: |
NAS |
| 2008 Sales: |
1,590,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
63 |
Business Description
Acadia Pharmaceuticals, Inc.. The Group's principal activity is to discover, develop and commercialize small molecule drugs for the treatment of central nervous system disorders.It has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma both in collaboration with Allergan Inc and ACP-106 in IND-track development. The Group currently developing a portfolio consisting of four most advanced product candidates including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis and retained worldwide commercialization rights to pimavanserin. It operates in the United States and Europe.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
